Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

被引：0

作者：

A Ray

D S Das

Y Song

T Hideshima

Y-T Tai

D Chauhan

K C Anderson

机构：

[1] The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center,Department of Medical Oncology

[2] Dana-Farber Cancer Institute,undefined

[3] Harvard Medical School,undefined

来源：

Leukemia | 2018年 / 32卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：843 / 846

页数：3

共 50 条

[41] Tusamitamab ravtansine induces immunogenic cell death and synergizes with anti-PD-1 or anti-PD-L1 antibody combination in solid tumor [J].

Nicolazzi, Celine ;

Lefebvre, Anne-Marie ;

Moindrot, Nicolas ;

Larois, Christelle ;

Classe, Marion ;

Sidhu, Sukhvinder .

CANCER RESEARCH, 2024, 84 (06)

[42] MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity [J].

Xiong, Wei ;

Deng, Huanghao ;

Huang, Changkun ;

Zen, Chong ;

Jian, Chengzhu ;

Ye, Kun ;

Zhong, Zhaohui ;

Zhao, Xiaokun ;

Zhu, Liang .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2019, 1865 (02) :454-463

[43] Intraperitoneal anti-PD-L1 increases survival in a novel ovarian cancer model and its in vivo efficacy is influenced by baseline anti-tumor immunity of the host [J].

Mony, Jyothi ;

Zhang, Lixin ;

Tirodkar, Tejas ;

Elishaev, Esther ;

Brozick, Joan ;

Edwards, Robert P. ;

Vlad, Anda M. .

CLINICAL CANCER RESEARCH, 2015, 21

[44] ANTI-PD-L1/IL-15 KD033 ACTIVATED MACROPHAGES AND INDUCED ANTI-TUMOR IMMUNITY IN THE TUMOR-MICROENVIRONMENT [J].

Martomo, Stella ;

Wang, George ;

Polonskaya, Zhanna ;

Luna, Xenia ;

Lu, Dan ;

Patel, Jeegar .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 :A681-A681

[45] Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors [J].

Pei Zhang ;

Yang Du ;

Hua Bai ;

Zhijie Wang ;

Jianchun Duan ;

Xin Wang ;

Jia Zhong ;

Rui Wan ;

Jiachen Xu ;

Xiran He ;

Di Wang ;

Kailun Fei ;

Ruofei Yu ;

Jie Tian ;

Jie Wang .

BMC Medicine, 20

[46] Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors [J].

Zhang, Pei ;

Du, Yang ;

Bai, Hua ;

Wang, Zhijie ;

Duan, Jianchun ;

Wang, Xin ;

Zhong, Jia ;

Wan, Rui ;

Xu, Jiachen ;

He, Xiran ;

Wang, Di ;

Fei, Kailun ;

Yu, Ruofei ;

Tian, Jie ;

Wang, Jie .

BMC MEDICINE, 2022, 20 (01)

[47] M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine [J].

Knudson, Karin M. ;

Hicks, Kristin C. ;

Luo, Xiaoling ;

Chen, Jin-Qiu ;

Schlom, Jeffrey ;

Gameiro, Sofia R. .

ONCOIMMUNOLOGY, 2018, 7 (05)

[48] Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors (vol 32, pg 1932, 2018) [J].

Bae, Jooeun ;

Hideshima, Teru ;

Tai, Yu-Tzu ;

Song, Yan ;

Richardson, Paul ;

Raje, Noopur ;

Munshi, Nikhil C. ;

Anderson, Kenneth C. .

LEUKEMIA, 2024, 38 (05) :1189-1190

[49] Targeting the intrinsic signaling of PD-L1 in human monocytes by a novel PD-L1 antibody to promote anti-tumor immunity. [J].

Hsu, Michelle A. ;

Liu, Xin ;

Barham, Whitney ;

Hirdler, Jacob ;

Mao, Zhiming ;

Lucien, Fabrice ;

Dong, Haidong .

JOURNAL OF IMMUNOLOGY, 2023, 210 (01)

[50] BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC [J].

Wang, Huijin ;

Liu, Guangyao ;

Jin, Xinghan ;

Song, Shenglei ;

Chen, Songyao ;

Zhou, Peiqing ;

Li, Huan ;

Liang, Jianming ;

Li, Bo ;

Zhang, Changhua ;

He, Yulong .

JOURNAL OF CANCER, 2022, 13 (06) :2126-2137

← 1 2 3 4 5 →